GLP-1 RAs hold a prominent position in the diabetes and obesity treatment paradigm due to their multiple advantages, such as robust glycemic control, relatively low risk of hypoglycemia, favorable adherence, and cardiovascular benefits. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.